For several decades, gifted and incredibly prolific forger Mark Landis compulsively created impeccable copies of works by a variety of major artists, donating them to institutions across the country and landing pieces on many of their walls. ART AND CRAFT brings us into the cluttered and insular life of an unforgettable character just as he finds his foil in an equally obsessive art registrar.
You May Also Like
David Harewood had a psychotic breakdown and was sectioned in his 20s. David traces his steps, meeting young people living with psychosis and the NHS professionals who treat them.
Countdown 13 locations ranging from haunted houses to abandoned asylums and a slew of frightening places in between.
Pages from a Family Diary tells the story of 16-year-old Noah and his family as they try to take care of one another while battling against bigotry and Texasandapos; anti-LGBTQ+ legislation.
A documentary directed by Grammy- and Emmy Award-winning filmmaker Thom Zimny. The ninety-minute film combines never-before-seen footage of Springsteen and the E Street Band shot between 1976 and 1978—including home rehearsals and studio sessions—with new interviews with Springsteen, E Street Band members, manager Jon Landau, former-manager Mike Appel, and others closely involved in the making of the record.
A documentary which explores the connections among sound, rhythm, time, and the body by following percussionist Evelyn Glennie, who is nearly deaf.
A team of experts analyse the case of Melissa Caddick and question where she could have gone after she disappeared, taking with her millions of dollars that she had swindled from her friends and family.
WORST TO FIRST is a feature-length documentary that portrays the against-all-odds inspirational story of the launch of the iconic and most successful radio station in history, New York City’s Z100.
Anthony Wonke directs this documentary marking the 25th anniversary of the Piper Alpha oil rig disaster. Re-examining the events that led to the drilling platform, at the time the largest and oldest in the North Sea oilfield, exploding on the night of the 6th July 1988, killing 167 men, the film includes testimonies from rescuers and some of the 61 survivors, many of whom were forced to jump hundreds of feet into a flaming, oil-covered sea, and discovers what the physical and psychological legacy of the disaster has meant for those involved.
Miss You Can Do It chronicles Abbey Curran, Miss Iowa USA 2008 and the first woman with a disability to compete at the Miss USA Pageant, and eight girls with various physical and intellectual disabilities as the girls participate in the Miss You Can Do It Pageant. Abbey founded the annual Miss You Can Do It Pageant in 2004 and girls and their families travel from all around the country to participate in this one night where their inner beauty and abilities reign.
Examining the violent death of the filmmaker’s brother and the judicial system that allowed his killer to go free, this documentary interrogates murderous fear and racialized perception, and re-imagines the wreckage in catastrophe’s wake, challenging us to change.
When professional mountain biker Paul Basagoitia suffers a devastating spinal cord injury (SCI), his life is changed in an instant. Discovering that he’s become paralyzed, Paul begins a grueling battle against his own body and mind, in the hope of one day being able to walk again. A chorus of other diverse SCI survivors weaves through the film, shining light on the struggles that Paul now faces.
Burzynski, the Movie is the story of a medical doctor and Ph.D biochemist named Dr. Stanislaw Burzynski who won the largest, and possibly the most convoluted and intriguing legal battle against the Food & Drug Administration in American history. His victorious battles with the United States government were centered around Dr. Burzynski’s gene-targeted cancer medicines he discovered in the 1970’s called Antineoplastons, which have currently completed Phase II FDA-supervised clinical trials in 2009 and could begin the final phase of FDA testing in 2011–barring the ability to raise the required $300 million to fund the final phase of FDA clinical trials.